Hunan Fangsheng Pharm Co Ltd - Asset Resilience Ratio

Latest as of June 2026: 2.43%

Hunan Fangsheng Pharm Co Ltd (603998) has an Asset Resilience Ratio of 2.43% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 603998 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥75.00 Million
≈ $10.97 Million USD Cash + Short-term Investments

Total Assets

CN¥3.09 Billion
≈ $452.38 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2023)

This chart shows how Hunan Fangsheng Pharm Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 603998 current and non-current assets.

Liquid Assets Composition Over Time

This chart breaks down Hunan Fangsheng Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 603998 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥75.00 Million 2.43%
Total Liquid Assets CN¥75.00 Million 2.43%

Asset Resilience Insights

  • Limited Liquidity: Hunan Fangsheng Pharm Co Ltd maintains only 2.43% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Hunan Fangsheng Pharm Co Ltd Industry Peers by Asset Resilience Ratio

Compare Hunan Fangsheng Pharm Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
Drug Manufacturers - Specialty & Generic 2.79%
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Beijing Tongrentang Co Ltd
SHG:600085
Drug Manufacturers - Specialty & Generic 2.51%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Harbin Pharmaceutical Group Co Ltd
SHG:600664
Drug Manufacturers - Specialty & Generic 0.97%
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%

Annual Asset Resilience Ratio for Hunan Fangsheng Pharm Co Ltd (2019–2023)

The table below shows the annual Asset Resilience Ratio data for Hunan Fangsheng Pharm Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 0.66% CN¥20.33 Million
≈ $2.97 Million
CN¥3.08 Billion
≈ $450.85 Million
-0.72pp
2022-12-31 1.38% CN¥40.31 Million
≈ $5.90 Million
CN¥2.92 Billion
≈ $427.60 Million
+0.81pp
2021-12-31 0.57% CN¥15.42 Million
≈ $2.26 Million
CN¥2.70 Billion
≈ $395.75 Million
+0.56pp
2020-12-31 0.01% CN¥296.24K
≈ $43.35K
CN¥2.24 Billion
≈ $328.19 Million
0.00pp
2019-12-31 0.01% CN¥287.48K
≈ $42.07K
CN¥1.99 Billion
≈ $291.92 Million
--
pp = percentage points

About Hunan Fangsheng Pharm Co Ltd

SHG:603998 China Drug Manufacturers - Specialty & Generic
Market Cap
$675.92 Million
CN¥4.62 Billion CNY
Market Cap Rank
#10908 Global
#3039 in China
Share Price
CN¥10.52
Change (1 day)
-1.77%
52-Week Range
CN¥8.85 - CN¥13.01
All Time High
CN¥18.09
About

Hunan Fangsheng Pharmaceutical Co., Ltd. engages in research, develops, produces, and sells traditional Chinese medicine industry and chemical pharmaceutical products in China. The company offers pharmaceutical manufacturing; and provides cardiovascular and cerebrovascular drugs, skeletal muscle system drugs, orthopedic drugs, respiratory drugs, pediatric drugs, neurological drugs, gynecological … Read more